Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 672, pseudogene (RN7SL672P) is classified as a pseudogene related to the 7SL RNA component of the signal recognition particle (SRP)[1][4][5]. Pseudogenes are noncoding genomic DNA sequences similar to normal genes but are typically non-functional due to mutations, truncations, or lack of regulatory elements[5][6]. As a pseudogene, RN7SL672P does not encode a functional RNA or protein, nor does it act as a receptor, enzyme, transporter, or other canonical drug target[1][4][5]. Most 7SL pseudogenes, including RN7SL672P, have resulted from reverse-transcribed 7SL RNA integrating back into the genome, and do not have known biological function or disease relevance[5][6]. There is no evidence linking RN7SL672P to therapeutic targeting, disease roles, drug interactions, or biomarker utility. Clarification on Use and Relevance: While functional 7SL RNA is essential for protein trafficking in cells as part of the SRP complex[3][7], *RN7SL672P* itself is a **pseudogene** and is not used as a therapeutic target. Its entry as a drug target would be considered incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 672, pseudogene (RN7SL672P).